# CIK Cell Transfusion Plus Chemotherapy as Adjuvant Therapy for Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC)

> **NCT01533727** · PHASE2 · WITHDRAWN · sponsor: **Sun Yat-sen University**

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Autologous CIK Transfusion plus Chemotherapy
- **DRUG:** chemotherapy alone

## Key facts

- **NCT ID:** NCT01533727
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-08
- **Primary completion:** 2017-12
- **Final completion:** 2020-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Few patients would like to participate ,since CIK cell transfusion was a new treatment and its efficacy was doubted.
- **Last updated:** 2013-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01533727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01533727, "CIK Cell Transfusion Plus Chemotherapy as Adjuvant Therapy for Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01533727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*